annb0t
Top 20
CSL (ASX:CSL) Full Year 2024 Results
Key Financial Results
Revenue: US$14.8b (up 11% from FY 2023). Net income: US$2.64b (up 20% from FY 2023). Profit margin: 18% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. EPS: US$5.47 (up from US$4.55 in FY 2023).
CSL Post-Clinical Trial Products
Pre-registration: 3. revenue-and-expenses-breakdown
All figures shown in the chart above are for the trailing 12 month (TTM) period
CSL EPS Misses Expectations
Revenue was in ...
>>> Read more: CSL Full Year 2024 Earnings: EPS Misses Expectations
Key Financial Results
Revenue: US$14.8b (up 11% from FY 2023). Net income: US$2.64b (up 20% from FY 2023). Profit margin: 18% (up from 17% in FY 2023). The increase in margin was driven by higher revenue. EPS: US$5.47 (up from US$4.55 in FY 2023).
CSL Post-Clinical Trial Products
Pre-registration: 3. revenue-and-expenses-breakdown
All figures shown in the chart above are for the trailing 12 month (TTM) period
CSL EPS Misses Expectations
Revenue was in ...
>>> Read more: CSL Full Year 2024 Earnings: EPS Misses Expectations
